Kanawha Capital Management LLC Has $24.87 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Kanawha Capital Management LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.8% during the first quarter, Holdings Channel reports. The firm owned 149,938 shares of the company’s stock after buying an additional 4,079 shares during the period. Johnson & Johnson comprises 1.9% of Kanawha Capital Management LLC’s holdings, making the stock its 12th biggest holding. Kanawha Capital Management LLC’s holdings in Johnson & Johnson were worth $24,866,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Lantz Financial LLC grew its position in Johnson & Johnson by 3.3% in the first quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock valued at $1,986,000 after acquiring an additional 377 shares during the period. Sulzberger Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter worth about $453,000. Horan Securities Inc. increased its position in shares of Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after purchasing an additional 90 shares in the last quarter. State of Wyoming lifted its holdings in Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company’s stock valued at $1,487,000 after purchasing an additional 10,279 shares during the last quarter. Finally, Joel Isaacson & Co. LLC boosted its position in Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock valued at $12,294,000 after buying an additional 2,526 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 0.2%

JNJ opened at $155.90 on Friday. The firm has a 50 day simple moving average of $153.65 and a 200 day simple moving average of $153.96. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a market cap of $375.11 billion, a price-to-earnings ratio of 17.34, a price-to-earnings-growth ratio of 2.35 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The company had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a $1.30 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.34%. Johnson & Johnson’s dividend payout ratio is presently 57.84%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Bank of America dropped their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, April 10th. Wall Street Zen raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 21st. Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Barclays lowered their target price on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research note on Thursday, April 17th. Finally, Leerink Partners lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.